Iron Technology: PharmaNutra | Enhancing Absorption | Efficacy | Iron Supplements

Since 2003, the scientific research activities of PharmaNutra, a group of companies specialized in the development, production, and distribution of raw materials (active ingredients) for the pharmaceuticals and nutraceuticals market, have focused on recognizing a more compelling and safe method for tackling issues related to iron intake. This involves preventing and addressing deficiencies of this valuable mineral and offering supplementation in clinical areas where iron deficiency occurs.

Thanks to the collaboration with top Italian universities and several foreign research foundations, PharmaNutra has been conducting clinical and fundamental research across a wide range of medical fields. The research demonstrates how Sucrosomial® Iron represents a significant alternative to conventional iron supplements on the market. Major benefits include a reduction in gastrointestinal tolerance issues, improved patient compliance, decreased need for blood transfusions and intravenous iron supplementation, and reduced healthcare costs. Recent publications have focused on cardiology, gastroenterology, nephrology, and cardiovascular surgery.

The following are some bibliographic references from the latest scientific studies:

• Karavidas An et al. Oral Sucrosomial iron improves exercise capacity and quality of life in heart failure with reduced ejection fraction and iron deficiency: A nonrandomized, open-label, proof-of-concept study. Eur J Heart Fail 2021 Jan 9.
• Bertani L et al. Oral Sucrosomial Iron is as effective as intravenous Ferric Carboxy-Maltose in treating anemia in patients with Ulcerative Colitis. Supplements 2021, 13, 608.
• Bastida G et al. Sucrosomial Iron supplementation for the treatment of iron deficiency anemia in Inflammatory Bowel Disease patients refractory to oral iron treatment. Supplements 2021, 13, 1770.
• Asperti M et al. Iron distribution in various tissues of homozygous Mask (msk/msk) mice and the effects of oral iron treatments. Am J Hematol. 2021;1–11.
• Reggiani F et al. Initial experience on the use of sucrosomial iron in hemodialysis: Focus on safety, hemoglobin maintenance, and oxidative stress. Int Urol Nephrol. 2021 Sep 12.
• Mazgaj R et al. Comparative evaluation of Sucrosomial Iron and iron oxide nanoparticles as oral supplements in iron deficiency anemia in piglets. Int J Mol Sci. 2021 Sep 14;22(18):9930.
• Zakrzewski M et al. Supplementation with Sucrosomial iron induces positive changes in the gut microbiome compared to ferrous sulfate in mice.

Source: PharmaNutra S.P.A